Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2014; 60(1): 98-103

Pathophysiological mechanisms of portal hypertension syndrome development

Romaniuk TV, Dziubanovs'kyĭ IIa, Kuziv OV.

    Gorbachevsky Medical University, Ternopil, Ukraine
DOI: https://doi.org/10.15407/fz60.01.098


Abstract

This review presents modern understanding of the patho- physiological mechanisms which lead to intrahepatic portal hypertension syndrome, as well as the development of main complications, such as esophageal varices, cardial bleeding, ascites, hypersplenism.

Keywords: pathogenesis, portal hypertension syndrome, complications of portal hypertension.

Full text: (PDF, in Ukrainian)

References

  1. Andreew G.N. Pathogenesis, diagnosis, treatment and organization of care for patients with chronic liver diseases. V. Novgorod; 2004.
    2.  
  2. Angermayr B., Fernandez M., Mejias M. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats. Gut. 2007; 56(4):560-564. CrossRef PubMed PubMedCentral
    3.  
  3. Assela T., Boyer N., Gimont M.K. In chronic hepatitis C liver fibrosis is associated with the severity of necrosis and inflammation, but not with steatosis. Hepatology. 2003, 6:50-55.
    4.  
  4. Carmeliet P. Manipulating angiogenesis in medicine. J. Intern. Med. 2004; 255(5):538-561. CrossRef PubMed
    5.  
  5. Chen Y., Wang C.P., Lu Y.Y. Hepatic stellate cells may by potential effectors of platelet activating factor induced portal hypertension. World J. Gastroenterol. 2008; 14(2):218-223. CrossRef PubMed PubMedCentral
    6.  
  6. Cichoz-Lach H., Celinski K., Slomka M., Kasztelan- Szczerbinska B. Pathophysiology of portal hypertension.J. Physiol. Pharmacol. 2008; 59(2):231-238. PubMed
    7.  
  7. Coll M., Martell M., Raurell I. Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver Int. 2010; 30(4):593-602. CrossRef PubMed
    8.  
  8. Garbuzenko D.B. Possibility of reducing portal pressure by small bowel resection in experimental and clinical. In: Collection scientific works department Surgical Clinic of Chelyabinsk Medical Institute: "Topical Issues surgery of abdominal and thoracic cavity"; 1992. P. 40-45.
    9.  
  9. Garbuzenko D.B. Bleeding from esophageal varices and gastric patients with liver cirrhosis: pathogenesis, prevention and treatment. Chelyabinsk: Publishing house «Eastern Gate»; 2004.
    10.  
  10. Garbuzenko D.B. Pathophysiological mechanisms and new directions therapy of portal hypertension in liver cirrhosis. Clinical. Gastroenterol., Hepatol. Prospects. 2010; 6:11-20.
    11.  
  11. Garbuzenko D.B., Bordunovsky V.N., Shadryncev A.N., Burulev A.L. Causes of bleeding varices of the esophagus in patients with liver cirrhosis. Hieroglyph. 1999; 6:28-30.
    12.  
  12. Fiorucci S., Antonelli E., Morelli A. Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver. Dig. Liver Dis. 2003; 35(2):61-69. CrossRef  
  13. Gatta A., Bolognesi M., Merkel C. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Mol. Aspects Med. 2008; 29(1-2):119-129. CrossRef PubMed
    14.  
  14. Graupera M., Garcia-Pagan J.C., Abraldes J.G. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology. 2003; 37(1):172-181. CrossRef PubMed
    15.  
  15. Hernandez-Guerra M., Garcia-Pagan J.C., Turnes J. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology.2006; 43:485-491. CrossRef PubMed
    16.  
  16. Kinoshita K., Iimuro Y., Otogawa K. Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut. 2007; 5:706-714. CrossRef PubMed PubMedCentral
    17.  
  17. Kulesha V.F. Portal hypertension. Blagoveshchensk: Amursk Stat. Med. Academy; 2011.
    18.  
  18. Kushnir I.E. Portal hypertension: from pathophysiology to treatment. Modern gastroenterology. 2009; 1(45):86-92.
    19.  
  19. Lazutkin M.V. Surgical correction of hypersplenism in patients with portal hypertension. Sergei Kirov Military Medical Academy, 2006. 131.
    20.  
  20. Lee J.S., Semela D., Iredale J., Shah V.H. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?. Hepatology. 2007; 45(3):817-825. CrossRef PubMed
    21.  
  21. Liu D., Chen J., Wang J. Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. Int. J. Mol. Med. 2010; 25(6):845-851. PubMed
    22.  
  22. Lugo-Baruqui A., Munoz-Valle J.F., Arevalo-Gallegos S., Armendariz-Borunda J. Role of angiotensin II in liver fibrosisinduced portal hypertension and therapeutic implications . Hepatol. Res. 2010; 40(1):95-104. CrossRef PubMed
    23.  
  23. Majid S., Azam Z., Shah H.A. Factors determining the clinical outcome of acute variceal bleed in cirrhotic patients. Indian J. Gastroenterol. 2009; 28(3):93-95. CrossRef PubMed
    24.  
  24. Martell M., Coll M., Ezkurdia N. Physiopathology of splanchnic vasodilation in portal hypertension. World J. Hepatol. 2010; 2(6):208-220. CrossRef PubMed PubMedCentral
    25.  
  25. Moleda L., Jurzik L., Froh M. Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension. World J. Gastroenterol. 2010;16(15):1837-1844. CrossRef PubMed PubMedCentral
    26.  
  26. Ozatli D., Koksal A.S., Haznedaroglu I.C. Anemias in Chronic Liver Diseases. Hematology. 2000; 5(1):69-76. CrossRef PubMed
    27.  
  27. Rusin A.V. Integrated staged treatment of portal hypertension complicated by ascitic syndrome. Kharkiv National Medical University. 2005.
    28.  
  28. Sancho-Bru P., Bataller R., Colmenero J. Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 291(5):877-884. CrossRef PubMed
    29.  
  29. Schogolev A.A., Al Sabanchi O.A., Miziano S.A., Grooms D. New technologies in treatment of bleeding varices esophagus and stomach. Russian Journal of Medicine.2002; 4:41-43.
    30.  
  30. Sherlock Sh. July J. Diseases of the liver and biliary tract.Moscow: GEOTAR Medicine; 1999.
    31.  
  31. Turmahanov S.T. Role azygos vein in pathogenesis varices and bleeding stomach varices in pations with portal hypertension.Novgorod State University. Medical Education Institute; 2002.
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.